These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24369317)

  • 1. The history of 5-ASA compounds and their use in ulcerative colitis--trailblazing discoveries in gastroenterology.
    Mayberry J
    J Gastrointestin Liver Dis; 2013 Dec; 22(4):375-7. PubMed ID: 24369317
    [No Abstract]   [Full Text] [Related]  

  • 2. How the discovery of TNF-α has advanced gastrointestinal diseases and treatment regimes.
    St-Pierre J; Chadee K
    Dig Dis Sci; 2014 Apr; 59(4):712-5. PubMed ID: 24504593
    [No Abstract]   [Full Text] [Related]  

  • 3. [Ulcerative colitis: major components of diagnostics and treatment].
    Rumiantsev VG
    Eksp Klin Gastroenterol; 2007; (2):80-5. PubMed ID: 17539350
    [No Abstract]   [Full Text] [Related]  

  • 4. MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
    Hu MY; Peppercorn MA
    Expert Opin Pharmacother; 2008 Apr; 9(6):1049-58. PubMed ID: 18377346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Toronto consensus guidelines for nonhospitalized ulcerative colitis: a welcome update but not the end of the story.
    Ananthakrishnan AN; Kane SV
    Gastroenterology; 2015 May; 148(5):877-80. PubMed ID: 25805424
    [No Abstract]   [Full Text] [Related]  

  • 6. Balsalazide disodium for the treatment of ulcerative colitis.
    Patil SA; Moss AC
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):177-84. PubMed ID: 19072352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis.
    Zhao X; Li N; Ren Y; Ma T; Wang C; Wang J; You S
    PLoS One; 2016; 11(8):e0160500. PubMed ID: 27501314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient Early Drug Development for Ulcerative Colitis.
    Khanna R; Jairath V; Vande Casteele N; Mosli MH; Zou G; Parker CE; Levesque BG; Sandborn WJ; D'Haens G; Feagan BG
    Gastroenterology; 2016 May; 150(5):1056-1060. PubMed ID: 27018491
    [No Abstract]   [Full Text] [Related]  

  • 9. Overview of 50 years' progress in upper gastrointestinal diseases.
    Yeomans ND
    J Gastroenterol Hepatol; 2009 Oct; 24 Suppl 3():S2-4. PubMed ID: 19799693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Year 1977: The active component of sulphasalazine is 5-aminosalycilic acid.
    Gomollón F; Marín-Jiménez I
    Gastroenterol Hepatol; 2020; 43(7):369-370. PubMed ID: 32713495
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of budesonide in collagenous colitis Evaluation of: Miehlke S, Madisch A, Kupcinskas L, et al. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. Gastroenterology 2014;146(5):1222-1230 e1222.
    Drug VL; Antoniu SA
    Expert Opin Pharmacother; 2014 Oct; 15(15):2277-9. PubMed ID: 25164577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Medical therapy of ulcerative colitis].
    Brand S
    MMW Fortschr Med; 2015 Feb; 157(2):45-8. PubMed ID: 25743521
    [No Abstract]   [Full Text] [Related]  

  • 13. [Contemporary views on non-specific ulcerative colitis and conservative methods of its treatment ].
    Bakulin IG; Stanke DA
    Voen Med Zh; 2008 Nov; 329(11):50-4. PubMed ID: 19186525
    [No Abstract]   [Full Text] [Related]  

  • 14. 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.
    Walker AM; Szneke P; Bianchi LA; Field LG; Sutherland LR; Dreyer NA
    Am J Gastroenterol; 1997 May; 92(5):816-20. PubMed ID: 9149192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical treatment of ulcerative colitis. Some reflections.
    Banks C; Forbes A
    Dig Liver Dis; 2007 Apr; 39(4):338-41. PubMed ID: 17317345
    [No Abstract]   [Full Text] [Related]  

  • 16. [Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
    Fallingborg JF
    Ugeskr Laeger; 2006 May; 168(21):2049-51. PubMed ID: 16768921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gastroenterology and hepatology. Using established therapies].
    MMW Fortschr Med; 2010 Dec; 152(48):50-1. PubMed ID: 21222338
    [No Abstract]   [Full Text] [Related]  

  • 18. [Management of ulcerative colitis].
    Rammert Ch; Kullak-Ublick GA
    Ther Umsch; 2003 Mar; 60(3):145-50. PubMed ID: 12693317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis.
    Cravo ML; Ferreira PA; Sousa P; Moura-Santos P; Velho S; Tavares L; de Deus JR; Ministro P; Peixe P; Correia LA; Velosa JF; Maio RF; Brito M
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):26-32. PubMed ID: 24168842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyostomatitis vegetans: A clinical marker of silent ulcerative colitis.
    Markiewicz M; Suresh L; Margarone J; Aguirre A; Brass C
    J Oral Maxillofac Surg; 2007 Feb; 65(2):346-8. PubMed ID: 17236948
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.